August 4, 2014

The Food and Drug Administration approved Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are younger than 8 years of age.

March 11, 2014

Prasco Laboratories announced on Tuesday that it has started shipping the generic version of Hectorol (doxercalciferol) 0.5-, 1.0- and 2.5-mcg capsules, each in 50-count bottles under the Prasco label.

February 6, 2014

Sandoz announced the launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol.

December 30, 2013

The Food and Drug Administration has declined to approve a drug made by Genzyme Corp. for certain forms of multiple sclerosis, the company said Monday.

March 22, 2013

Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

January 30, 2013

The Food and Drug Administration has approved a new drug for treating a rare cholesterol disorder, the agency said.

January 28, 2013

The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

October 2, 2012

An experimental drug for treating a rare genetic disease appears effective, according to a late-stage clinical trial.

September 13, 2012

The Food and Drug Administration has approved a new drug for multiple sclerosis.

September 4, 2012

Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.

August 27, 2012

Genzyme announced it has received a refuse-to-file letter from the Food and Drug Administration in response to the drug maker's supplemental biologics license application for the approval of Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis.

July 31, 2012

Abon Pharmaceuticals is challenging the patent protection on an injected drug used to treat leukemia in children and adolescents, the company said Tuesday.

June 12, 2012

A Sanofi company is seeking regulatory approval from the Food and Drug Administration for a drug designed to treat relapsing multiple sclerosis.

May 3, 2012

Drug makers could strike big with new treatments for rare diseases, according to a new report by a market research firm.

April 20, 2012

Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.

January 24, 2012

The Food and Drug Administration has approved a new manufacturing plant that will be operated by drug maker Genzyme.

December 21, 2011

An orally administered drug made by Genzyme for treating multiple sclerosis did not appear superior to a biotech drug already on the market, according to results of a late-stage clinical trial.

November 14, 2011

A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

November 10, 2011

Genzyme has named leaders of two units that are part of the core focus of the drug maker's business.

October 25, 2011

Sanofi has appointed David Meeker as CEO of Genzyme, the French drug maker said.

October 11, 2011

A drug maker that focuses on treatments for hemophilia has named a new CEO.

September 15, 2011

GlaxoSmithKline and Amicus Therapeutics have started a late-stage clinical trial for a drug to treat a rare genetic disorder, the companies said.

June 30, 2011

Impax Labs has agreed not to market a generic version of a drug designed to reduce blood sugar and cholesterol in tablet form until 2015.

April 11, 2011

Genzyme now officially is a wholly owned subsidiary of Sanofi-Aventis.